<DOC>
	<DOCNO>NCT00386516</DOCNO>
	<brief_summary>The purpose clinical trial determine whether combination establish chemotherapeutic agent 5-fluorouracil ( 5-FU ) large carbohydrate molecule GM-CT-01 beneficial treating advance gall bladder bile duct cancer .</brief_summary>
	<brief_title>Study Test Benefit Safety GM-CT-01 Combination With 5-FU Treat Bile Duct Gall Bladder Cancer</brief_title>
	<detailed_description>Determine overall response rate ( ORR ) define complete response ( CR ) rate plus partial response ( PR ) rate use Response Evaluation Criteria Solid Tumors ( RECIST ) , well stable disease ( SD ) rate subject unresectable , locally advanced metastatic cholangiocarcinoma biliary tract tumor treat GM-CT-01 plus 5-Fluorouracil ( DAVFU ) dose 280 mg/m2 600 mg/m2 , respectively , cycle 4 consecutive day treatment follow 24-day follow-up period .</detailed_description>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . 18 year age old . 2 . Histologically cytologically document carcinoma primary intra extrahepatic biliary system gall bladder clinical and/or radiologic evidence unresectable , locally advanced metastatic disease . 3 . Prior neoadjuvant adjuvant therapy ( include radiation therapy ) allow provide complete least 4 week document disease recurrence metastasis . 4 . Discontinuation radiation therapy least 3 week prior Day 1 Cycle 1 . Radiation therapy allow subject study except palliative radiation therapy nontarget lesion administer follow consultation Medical Monitor . 5 . Prior surgery must complete least 14 day prior Day 1 Cycle 1 . 6 . Nne measurable target lesion ( ) accord RECIST . Measurable lesion ( ) must outside previous radiation field demonstrate clear radiographic progression serial image within previous treatment field . 7 . ECOG performance status less equal 2 . 8 . Life expectancy great equal 3 month . 1 . Central nervous system metastasis . 2 . Bony metastasis sole metastasis . 3 . Received prior chemotherapy antiangiogenesis agent include bevacizumab erbitux radiation therapy neoadjuvant adjuvant setting . No concomitant chemotherapy , antitumor biologic therapy , radiation therapy allow . 4 . If nitrosoureas mitomycin C use neoadjuvant adjuvant therapy , least 6 week elapse prior treatment DAVFU . 5 . Active infection require treatment systemic antibiotic , anti fungal . antiviral therapy . 6 . Congestive heart failure ( Class III IV NYHA functional classification system ) medical condition would preclude IV administration approximately 200 mL fluid 3060 minute . 7 . Unresolved biliary tract obstruction . 8 . Known clinically suspected infection HIV . 9 . Subject know intolerance 5 FU .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>bile duct</keyword>
	<keyword>biliary</keyword>
	<keyword>intra-hepatic</keyword>
	<keyword>extra-hepatic</keyword>
	<keyword>gall bladder</keyword>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>metastasis</keyword>
	<keyword>advanced</keyword>
	<keyword>recurrent</keyword>
</DOC>